Amarin Corporation PLC

Amarin Corporation PLC is a biopharmaceutical company that specializes in developing and commercializing therapeutics for cardiovascular diseases. Its lead product, Vascepa, is a prescription omega-3 fatty acid medication approved by the US FDA for severe hypertriglyceridemia. Amarin is also conducting clinical trials to evaluate Vascepa's potential in reducing cardiovascular events in patients with elevated triglyceride levels. The company is dedicated to advancing cardiovascular disease science and improving patient outcomes through innovative research and development. Headquartered in Dublin, Ireland, Amarin operates in the US and other countries.